k-Strophanthin-alpha

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: k-Strophanthin-alpha
• 英文别名: (3S,5S,8S,9S,10S,13R,14S,17R)-5,14-dihydroxy-3-[(2R,4S,5R,6R)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-13-methyl-17-(5-oxo-2H-furan-3-yl)-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-10-carbaldehyde
• 化学式: C₃₀H₄₄O₉
• 分子量: 548.7
• InChiKey: XQCGNURMLWFQJR-JHVHLWGGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  39
• 可旋转键数：
  5
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.87
• 拓扑面积：
  132
• 氢给体数：
  3
• 氢受体数：
  9

文献信息

• Substituted amides for treating and preventing cancer
  申请人：The Regents of the University of Michigan

  公开号：US10457662B2

  公开（公告）日：2019-10-29

  This invention is in the field of medicinal chemistry. In particular, the invention relates to novel small molecule compounds having a quinolin-8-yl-nicotinamide structure (e.g., a compound having Formula I: which are useful in treating, ameliorating, or preventing various forms of cancer (e.g., pancreatic cancer).

  本发明属于药物化学领域。特别是，本发明涉及具有喹啉-8-基烟酰胺结构的新型小分子化合物（例如，具有式 I.A.B.C 的化合物）： 其有助于治疗、改善或预防各种形式的癌症（如胰腺癌）。
• Method and compositions for treating viral infections
  申请人：PHOENIX BIOTECHNOLOGY, INC.

  公开号：US10596186B2

  公开（公告）日：2020-03-24

  A method of treating viral infection, such as viral infection caused by a virus of the Filoviridae, Flaviviridae or Togaviriade family, is provided. A composition having at least one cardiac glycoside is used to treat viral infection. The composition can further include at least one triterpene.

  提供了一种治疗病毒感染的方法，例如由丝状病毒科、弗拉维病毒科或 Togaviriade 科病毒引起的病毒感染。一种含有至少一种强心苷的组合物用于治疗病毒感染。该组合物可进一步包括至少一种三萜。
• Method and compostitions for treating coronavirus infection
  申请人：PHOENIX BIOTECHNOLOGY, INC.

  公开号：US10729735B1

  公开（公告）日：2020-08-04

  A method of treating viral infection, such as viral infection caused by a virus of the Coronaviridae family, is provided. A composition having at least oleandrin is used to treat viral infection.

  提供了一种治疗病毒感染的方法，例如由冠状病毒科病毒引起的病毒感染。一种至少含有齐墩果素的组合物用于治疗病毒感染。
• Method and compositions for treating viral infection
  申请人：PHOENIX BIOTECHNOLOGY, INC.

  公开号：US10702567B2

  公开（公告）日：2020-07-07

  A method of treating viral infection, such as viral infection caused by a virus of the Filoviridae family, Flaviviridae family (Flavivirus genus), Deltaretrovirus genus, or Togaviriade family is provided. A composition having at least one cardiac glycoside is used to treat viral infection. The composition can further include at least one triterpene. Alternatively, the composition comprises at least one, at least two, or at least three triterpenes.

  提供了一种治疗病毒感染的方法，例如由丝状病毒科、黄热病病毒科（黄热病病毒属）、Deltaretrovirus属或Togaviriade科病毒引起的病毒感染。具有至少一种强心苷的组合物用于治疗病毒感染。该组合物可进一步包括至少一种三萜。或者，该组合物包含至少一种、至少两种或至少三种三萜类化合物。
• Lipid-linked prodrugs
  申请人：The University of British Columbia

  公开号：US10780174B2

  公开（公告）日：2020-09-22

  This invention provides lipid-linked prodrugs having structures as set out herein. Uses of such lipid-linked prodrug compounds for treatment of various indications, and methods for making and using lipid-linked prodrugs are also provided.

  本发明提供了具有本文所述结构的脂联原药。本发明还提供了这种脂联原药化合物用于治疗各种适应症的用途，以及脂联原药的制造和使用方法。